Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present)

References

• Kotera J, Fujishige K, Yuasa K, et al. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun. 1999;261:551–557.
   PubMed Web of Science ®Google Scholar
• Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999;274:18438–18445.
   PubMed Web of Science ®Google Scholar
• MacMullen CM, Fallahi M, Davis RL. Novel PDE10A transcript diversity in the human striatum: insights into gene complexity, conservation and regulation. Gene. 2017;606:17–24.
   PubMed Web of Science ®Google Scholar
• Charych EI, Jiang L-X, Lo F, et al. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. J Neurosci. 2010;30:9027–9037.
   PubMed Web of Science ®Google Scholar
• Jäger R, Russwurm C, Schwede F, et al. Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem. 2012;287:1210–1219.
   PubMed Web of Science ®Google Scholar
• Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113–126.
   PubMed Web of Science ®Google Scholar
• Chappie TA, Helal CJ, Hou X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J Med Chem. 2012;55:7299–7331.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Hou J, et al. Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci USA. 2007;104:5782–5787.
   PubMed Web of Science ®Google Scholar
• Verhoest PR, Chapin DS, Corman M, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009;52:5188–5196.
   PubMed Web of Science ®Google Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366–398.
   PubMed Web of Science ®Google Scholar
• Bodén R, Persson J, Wall A, et al. Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study. Transl Psychiatry. 2017;7:e1050.
   PubMed Web of Science ®Google Scholar
• Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology. 2006;51:386–396.
   PubMed Web of Science ®Google Scholar
• Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51:374–385.
   PubMed Web of Science ®Google Scholar
• Nikiforuk A, Potasiewicz A, Rafa D, et al. The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors. Behav Pharmacol. 2016;27:331–338.
   PubMed Web of Science ®Google Scholar
• Niccolini F, Foltynie T, Reis Marques T, et al. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease. Brain. 2015;138:3003–3015.
   PubMed Web of Science ®Google Scholar
• Heckman PRA, Van Duinen MA, Bollen EPP, et al. Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol. 2016;19:1–16. Oxford University Press.
   PubMed Web of Science ®Google Scholar
• Giorgi M, D’Angelo V, Esposito Z, et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci. 2008;28:941–950.
   PubMed Web of Science ®Google Scholar
• Mitsubishi Tanabe Pharma. Treatment of Parkinson’s disease and enhancement of dopamine signal using PDE 10 inhibitor. US8338420B1. 2012
   Google Scholar
• Mehta A, Patel BM. Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors. Life Sci. 2019;230:150–161. Elsevier Inc.
   PubMed Web of Science ®Google Scholar
• Cantin LD, Magnuson S, Gunn D, et al. PDE-10A inhibitors as insulin secretagogues. Bioorganic Med Chem Lett. 2007;17:2869–2873.
   Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P. Phosphodiesterase 10 inhibitors in clinical development for CNS disorders. Expert Rev Neurother. 2017;17:553–560.
   PubMed Web of Science ®Google Scholar
• Zagorska A, Partyka A, Bucki A, et al. Phosphodiesterase 10 inhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery. Curr Med Chem. 2018;25:3455–3481.
   PubMed Web of Science ®Google Scholar
• Omeros Corp. Processes and intermediates for the preparation of PDE 10 inhibitor. WO 2015167969. 2015.
   Google Scholar
• Omeros Corp. PDE10 inhibitors and related composition and methods. US9650368B2. 2017.
   Google Scholar
• Omeros Corp. Optically active PDE10 inhibitor. US9850238. 2017.
   Google Scholar
• Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors. US8957077B2. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp. Aryloxymethyl cyclopropane derivatives as PDE10 inhibitors. US8975261B2. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp. Substituted pyridizinone derivatives as PDE10 inhibitors. US9353104B2. 2016.
   Google Scholar
• Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine PDE10 inhibitors. US9359348B2. 2016.
   Google Scholar
• Merck Sharp & Dohme Corp. Secondary alcohol substituted triazoles as PDE10 inhibitors. US9428492B2. 2016.
   Google Scholar
• H. Lundbeck A/S. Substituted imidazo[2,1-a]isoindoles as PDE10 inhibitors. US9062060B2. 2015;
   Google Scholar
• H. Lundbeck A/S. Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors. US9096589B2. 2015.
   Google Scholar
• H. Lundbeck A/S. Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors. US9669029B2. 2017.
   Google Scholar
• H. Lundbeck A/S. 2-Arylimidazole derivatives as PDE10a enzyme inhibitors. US8927738B2. 2015.
   Google Scholar
• AMGEN INC. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors. US8946230B2. 2015.
   Google Scholar
• AMGEN INC. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors. US8952037B2. 2015;
   Google Scholar
• AMGEN INC. Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors. US8957073B2. 2015.
   Google Scholar
• AMGEN INC. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors. US9376450B2. 2016.
   Google Scholar
• Janssen Pharmaceutica NV. Inhibitors of phosphodiesterase 10 enzyme. EP2869822B1. 2015.
   Google Scholar
• Janssen Pharmaceutica NV. Inhibitors of phosphodiesterase 10 enzyme. US9550784B2. 2017.
   Google Scholar
• Mitsubishi Tanabe Pharma. Pyrazolopyrimidine compounds and their use as PDE10 inhibitors. US8969376B2. 2015.
   Google Scholar
• Kotera J, Fujishige K, Michibata H, et al. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1- oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP- specific phosphodiesterase (PDE5). Biochem Pharmacol. 2000;60:1333–1341.
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors. US8969349B2. 2015.
   Google Scholar
• Sunovion Pharamaceuticals Inc. Substituted [1,2 4] triazolo[1, 5-a]pyrazine derivatives as phosphodiesterase inhibitors. US9994590B2. 2018.
   Google Scholar
• CELON PHARMA S.A. Fused triazole derivatives as phosphodiesterase 10A inhibitors. WO2015177688A1. 2015.
   Google Scholar
• CELON PHARMA S.A. Fused triazole derivatives as phosphodiesterase 10A inhibitors. US10138245B2. 2018.
   Google Scholar
• BRISTOL-MYERS SQUIBB COMPANY. Inhibitors of PDE10. WO2013003298. 2013.
   Google Scholar
• AbbVie Deutschland GmbH & Co KG. Inhibitors of phosphodiesterase type 10A. EP2776418B1. 2017.
   Google Scholar
• AbbVie Deutschland GmbH & Co KG. Novel inhibitor compounds of phosphodiesterase type 10A. US2018/0030033A1. 2018.
   Google Scholar
• AbbVie Deutschland GmbH & Co KG. Inhibitor compounds of phosphodiesterase type 10A. US10308610B2. 2019.
   Google Scholar
• PALOBIOPHARMA S.L. Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10). US9447095B2. 2016.
   Google Scholar
• Hoffmann-La Roche Inc. Triazolo compounds as PDE10 inhibitors. US9394311. 2016.
   Google Scholar
• Omeros Corp. PDE 10 inhibitors and related composition and methods. WO2016172573A1. 2016.
   Google Scholar
• Omeros Corp. PDE 10 inhibitors and related composition and methods. US8343970B2. 2013.
   Google Scholar
• Omeros Corp. PDE 10 inhibitors and related composition and methods. US86685975. 2014.
   Google Scholar
• Allergan Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodieterase 10 9PDE 10A. US9902710B2. 2018.
   Google Scholar
• Omeros Corp. Solid state forms of a PDE10 inhibitor. US2017016559A1. 2017.
   Google Scholar
• Omeros Corp. PDE 10 inhibitors and related composition and methods. WO2011112828. 2011.
   Google Scholar
• University of South Alabama. Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression. WO2015006689. 2015.
   Google Scholar
• Janssen Pharmaceutica NV. PDE 10a inhibitors for the treatment of type II diabetes. US9193736. 2015.
   Google Scholar
• Janssen Pharmaceutica NV. PDE10a inhibitors for the treatment of type II diabetes. US9249163. 2014.
   Google Scholar
• Macek TA, McCue M, Dong X, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019;204:289–294.
   PubMed Web of Science ®Google Scholar
• Marques TR, Natesan S, Niccolini F, et al. Phosphodiesterase 10A in Schizophrenia: A PET Study Using [11 C]IMA107. Am J Psychiatry. 2016;173:714–721.
   PubMed Web of Science ®Google Scholar
• Li Y-W, Seager MA, Wojcik T, et al. Biochemical and behavioral effects of PDE10A inhibitors: relationship to target site occupancy. Neuropharmacology. 2016;102:121–135.
   PubMed Web of Science ®Google Scholar